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Risk estimationAbstract Background: Clinical decision-making in patients with early stage breast cancer
requires adequate risk estimation by medical oncologists. This survey evaluates the agreement
among oncologists on risk estimations and adjuvant systemic treatment (AST) decisions and
the impact of adding the 70-gene signature to known clinico-pathological factors.
Methods: Twelve medical oncologists assessed 37 breast cancer cases (cT1–3N0M0) and esti-
mated their risk of recurrence (high or low) and gave a recommendation for AST. Cases wereterdam,
1046 C.A. Drukker et al. / European Journal of Cancer 50 (2014) 1045–1054presented in two written questionnaires sent 4 weeks apart. Only the second questionnaire
included the 70-gene signature result.
Results: The level of agreement among oncologists in risk estimation (j = 0.57) and AST
recommendation (j = 0.57) was ‘moderate’ in the ﬁrst questionnaire. Adding the 70-gene
signature result signiﬁcantly increased the agreement in risk estimation to ‘substantial’
(j = 0.61), while agreement in AST recommendations remained ‘moderate’ (j = 0.56).
Overall, the proportion of high risk was reduced with 7.4% (range: 6.9–22.9%; p < 0.001)
and the proportion of chemotherapy that was recommended was reduced with 12.2% (range:
5.4–29.5%; p < 0.001).
Conclusion: Oncologists’ risk estimations and AST recommendations vary greatly. Even
though the number of participating oncologists is low, our results underline the need for a
better standardisation tool in clinical decision-making, in which integration of the 70-gene
signature may be helpful in certain subgroups to provide patients with individualised, but
standardised treatment.
Crown Copyright  2014 Published by Elsevier Ltd. Open access under CC BY-NC-SA license. 1. Introduction
Clinico-pathological guidelines are used to guide
adjuvant systemic treatment (AST) decisions in early
stage breast cancer patients. These guidelines combine
clinico-pathological factors such as age, tumour size,
grade, hormone-receptor status and nodal status to esti-
mate the risk of recurrence and provide an AST advice.
Commonly used clinico-pathological guidelines are
Adjuvant! Online (AOL), the Sankt Gallen expert panel
recommendations and the Nottingham Prognostic Index
(NPI) [1,2]. In the Netherlands, the Dutch Institute of
Healthcare Improvement (CBO) guidelines are used
most often [3]. Nevertheless, correctly estimating
whether an individual patient has a high risk of recur-
rence and is likely to beneﬁt from AST remains challeng-
ing [4]. Most of the guidelines consider only a small
proportion of patients at a low risk of recurrence. This
may result in a substantial number of patients being trea-
ted with AST while they are unlikely to derive signiﬁcant
beneﬁt [5]. Each guideline mentioned above deﬁnes a
partly non-overlapping group of patients at a low or high
risk, which indicates that predictive accuracy for the indi-
vidual patient is not high [1,6–8]. Also, online tools such
as AOL that provide a survival probability instead of a
low/high risk estimation can be used with diﬀerent cut
oﬀs. Therefore, a variation in risk estimations made by
oncologists who are guided by diﬀerent guidelines is
expected. The extent of this variation remains unclear.
To reﬁne risk estimations and provide a more tailored
AST recommendation for the individual patient, gene
expression prognosis classiﬁers have been developed
[9]. One of these gene expression classiﬁers is the 70-gene
signature (MammaPrinte, Agendia Inc., Amsterdam,
The Netherlands) [10]. The ﬁrst prospective study, in
which the 70-gene signature was used in addition to clin-
ical guidelines, was conducted in the Netherlands
between 2004 and 2006. This microarRAy prognoSTicsin breast cancER (RASTER) study showed discordance
in risk estimation between the 70-gene signature and cli-
nico-pathological guidelines in one third of the patients
[11]. In daily clinical practice, medical oncologists are
using the 70-gene signature the same way as it was used
in the RASTER study, i.e. in addition to clinico-patho-
logical guidelines [1,11]. However, the impact of the 70-
gene signature on risk estimations and AST decisions in
daily clinical practice is unknown. The aim of this survey
was to determine the agreement among oncologists’ risk
estimations and AST recommendations based on clinic-
o-pathological factors as are used in clinical guidelines,
and to assess the impact of the 70-gene signature.
2. Methods
Two written questionnaires were developed (C.A.D.,
S.C.L., H.C.v.d.H., M.K.S.) and reviewed by an inde-
pendent oncologist (G.S.S.). Thirty-seven cases of breast
cancer patients were presented to 29 medical oncologists
specialised in breast cancer in Europe. The oncologists
were chosen because of their area of expertise and the
country they work in. We included oncologists from all
over Europe to not only demonstrate the situation among
oncologists in one country, but for an entire continent.
The oncologists were asked to indicate their use of clini-
cal guidelines and to give their risk estimation (high/low)
and recommendation of AST (none, endocrine therapy,
chemotherapy, trastuzumab or a combination) for each
case. Several weeks later, the same cases were presented
in a randomly changed order in a second questionnaire.
In this second questionnaire, the 70-gene signature result
was provided along with clinical characteristics.
2.1. Cases
To provide a reﬂection of true clinical practice, 37
cases of breast cancer patients were selected from the
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signature result. All cases involved women under
61 years, with unilateral, histological proven, operable
breast cancer (cT1–3N0M0). Of each patient tumour
size, histo-pathological grade, histological type, mitotic
index, hormone-receptor status and human epidermal
growth factor receptor 2 (HER2) status were described
(Supplementary Table 1). The actually received treat-
ments were not mentioned in the questionnaire.2.2. Clinical risk estimation based on Adjuvant! Online
Hereafter, risk estimations using clinico-pathological
factors will be referred to as ‘clinical risk’. In this survey,
the clinical risk estimation was ﬁrst assessed using AOL
version 8.0. Patients were assigned to a high clinical risk
if their AOL 10-year survival probability was less than
90% based on ‘minor problems’ regarding overall health
status, which is the default item of the online pro-
gramme [11]. Of the 37 cases, 10 cases were concordant
high, 12 concordant low and 15 discordant with the
70-gene signature result. The cases are a random
selection from stratiﬁcation of concordant low risk,
discordant and concordant high risk with the 70-gene
signature result.2.3. Clinical risk estimations by other guidelines
Additional risk estimations according to the St.
Gallen expert panel recommendations of 2003, NPI
and CBO 2004 (all versions were used at the time of
the RASTER study) were assessed previously [6,11–
13]. Diﬀerences among clinico-pathological guidelines,
tool and expert panel recommendations are summarised
in Table 1.
Risk estimations were concordant with the 70-gene
signature and all clinical guidelines in 12 cases, six were
concordant high risk and six concordant low risk. There
was discordance between the 70-gene signature and at
least one of the guidelines in 25 cases (68%).2.4. Statistical analysis
All data were analysed using SPSS 20.0 (SPSS Inc.).
Agreement among the oncologists as well as between
each oncologist and the 70-gene signature result (low
risk versus high risk) was assessed using kappa statistics.
A kappa of 0 means random, 0.01–0.20 slight agree-
ment, 0.21–0.40 fair agreement, 0.41–0.60 moderate
agreement, 0.61–0.80 substantial agreement, 0.81–0.99
almost perfect agreement and a kappa of 1 is perfect
agreement. The paired samples t-test was conducted to
compare the kappa means between the oncologists’ risk
estimations in the ﬁrst and second questionnaire. Logis-
tic regression models were used to assess the likelihood
of the 70-gene signature result leading to changes in riskestimations and AST recommendations. Co-variants
included in this model were age, tumour size, grade, his-
tological type, oestrogen receptor (ER) and HER2 sta-
tus. In case of an unanswered question in either the
clinical risk estimation or the estimation based on the
70-gene signature, these risk estimations were both
excluded from the analyses. A signiﬁcant ﬁnding was
deﬁned as a two-sided p-value below 0.05.3. Results
3.1. Participants and case characteristics
Nineteen oncologists completed the ﬁrst question-
naire (66%). Twelve oncologists (41%) also completed
the second questionnaire. Mean age of these oncologists
was 49 years (36–66 years) and they were practicing their
current profession on average for 18 years (2–35 years).
Six of the oncologists came from the Netherlands and
six from other European countries (Germany, France,
Italy and Portugal). Patient- and tumour-characteristics
of the 37 cases included in the analyses as well as their
risk estimations according to the 70-gene signature,
AOL and other clinical guidelines are summarised in
Supplementary Table 1. On average, for each case two
risk estimations and three AST recommendations were
missing per oncologist, i.e. not answered in the two
questionnaires.3.2. Risk estimations and AST recommendations
On average, the oncologists classiﬁed 51% (range 24–
65%) cases as clinically low risk and 47% (range 32–
76%) as clinically high risk. After adding the 70-gene sig-
nature result, the oncologists classiﬁed 59% (range 22–
78%) of the cases as low risk and 38% (range 22–78%)
as high risk (Fig. 1). On average, an oncologist changed
the given clinical risk estimation in 14.2% of the cases. In
10.8% of the cases high risk changed to low risk and in
3.4% of the cases low risk changed to high risk (Table 2).
This leads to a net reduction of 7.4% (range 6.9–22.9%)
in high risk classiﬁcations. In the 12 cases in which all
guidelines and the 70-gene signature were concordant
signiﬁcantly less changes in risk estimations were made
(3.5%) compared to the 25 cases in which one or more
of the guidelines and the 70-gene signature were discor-
dant (18%) (p < 0.0001).
The oncologists recommended AST based on
clinico-pathological factors in 95% (range 76–100%) of
the cases, chemotherapy (alone or combined) in 48%
(range 30–70%) and endocrine therapy (alone) in 46%
(range 0–70%) of the cases (Table 2, Fig. 2). After adding
the 70-gene signature result to the clinico-pathological
factors provided in the ﬁrst questionnaire, they recom-
mended AST in 93% (range 78–100%) of the cases, che-
motherapy (alone or combined) in 37% (range 22–68%)
Table 1
Clinico-pathological factors used by breast cancer guidelines and risk estimation tools to deﬁne patients at a low risk of recurrence.
Guideline/tool Age Size Grade Hist. type ER/PR HER2 Ki67 Nodal status Other factors Low risk is deﬁned as
AOL [8] Continuous Yes Yes Ductal, in case of
other hist. type,
information is
available online
ER No No Yes Co-morbidities, CT
regimen
Not speciﬁed
St. Gallen 2003 [7,12] <35 or P35 Yes Yes Not used ER and PR No No Node-negative None ER+ and PR+, grade I,
62 cm and age P35 years
St. Gallen 2009 [12] Not used Yes Yes Not used ER and PR No Yes Yes PVI, multigene
assays
High ER and PR, grade I,
low Ki67, node-negative,
absence of PVI, 620 mm,
low score on multigene assay
St. Gallen 2011 [20] Pre- or post
menopausal
No Yes Not used ER and PR Yes Yes Yes, more than 3+
nodes is high risk
Biological subtype Luminal A; ER+ and PR+,
HER2, low Ki67
NPI [6] Not used Yes Yes Not used No No No Yes None [0.2  Size] + Number of
nodes + Grade; low
risk = score lower than 3.4
CBO 2004 [13] <35 or P35 Yes Yes Not used No No No Yes None N0, P35 years, grade I
tumour 61 cm OR
>35 years, grade 1 630 mm
OR grade 2, 620 mm OR
grade 3 610 mm
CBO 2012 [3] <35 or P35 Yes Yes Not used No Yes No Yes None 10-years survival probability
P85%. N0, <35, grade I
tumour 61 cm OR
P35 years, grade I tumour
62 cm.
PREDICT [21] Yes Yes Yes Not used ER Yes Yes Yes Method of
detection, CT
regimen
Not speciﬁed. Suggested:
<3% survival beneﬁt in 10-
years no chemotherapy; 3–
5% chemotherapy discussed
as possible option
AOL = Adjuvant! Online; NPI = Nottingham Prognostic Index; CBO and NABON = Dutch guidelines; ER = oestrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth
factor receptor 2; CT = chemotherapy; PVI = peritumoural vascular invasion.
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Fig. 1. Changes in risk estimations per oncologist per case and risk estimations by clinico-pathological guidelines and the 70-gene signature.
Table 2
Changes in risk estimation and adjuvant systemic treatment (AST) recommendation after providing 70-gene signature result.
A. Changes in risk estimation (%)
CR 70GS
High risk Low risk Total CR
High risk 149 (35.8) 45 (10.8) 194 (46.6)
Low risk 14 (3.4) 208 (50) 222 (53.4)
Total 70GS 163 (39.2) 253 (60.8) 416C (100)
B. Changes in AST recommendation (%)
CR 70GS
No AST ChemotherapyA Endocrine therapyB Total CR
No AST 16 (3.9) 1 (0.2) 5 (1.2) 22 (5.3)
ChemotherapyA 2 (0.5) 144 (34.8) 57 (13.8) 203 (49)
Endocrine therapyB 10 (2.4) 8 (1.9) 171 (41.3) 189 (45.7)
Total 70GS 28 (6.8) 153 (37) 233 (56.3) 414C (100)
CR = clinical risk, estimations based on clinico-pathological factors, 70GS = 70-gene signature, result included in the questionnaire.
A Chemotherapy alone or combined with endocrine therapy and/or trastuzumab.
B Endocrine therapy alone.
C Missing values not included.
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24% of the cases the oncologist adjusted the AST recom-
mendation (Table 2). Adding the 70-gene signatureresulted in 14.3% of the cases in a change from chemo-
therapy to either endocrine therapy or no AST at all.
Only one oncologist advised more chemotherapy after
patient
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70-gene signature
Adjuvant! Online
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low risk
high risk
no CT
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no CT to CT
CT to no CT
CT to CT
Fig. 2. Changes in adjuvant systemic treatment (AST) recommendations per oncologist per case and the actual given treatment.
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cases the advice of no AST or endocrine therapy only was
changed to chemotherapy. This resulted in a reduction in
chemotherapy use of 12.2% (range: 5.4–29.5%) after add-
ing the 70-gene signature to known clinico-pathological
factors in the second questionnaire. In the 12 cases in
which all guidelines and the 70-gene signature were con-
cordant signiﬁcantly less changes in AST recommenda-
tions were made (4.2%) compared to the 25 cases in
which one or more of the guidelines and the 70-gene sig-
nature were discordant (20.7%) (p < 0.0001).
3.3. Agreement among oncologists
There was moderate level of agreement among oncol-
ogists in risk estimations based solely on clinico-patho-
logical factors (j = 0.57; range: 0.20–0.88) (Table 3).
The level of agreement in AST recommendation was
also moderate (j = 0.57; range: 0.24–0.84). After adding
the 70-gene signature result to clinico-pathological fac-tors, agreement in risk estimation increases slightly,
but signiﬁcantly to substantial (j = 0.61; range: 0.14–
1.00; p = 0.035), while the level of agreement regarding
AST recommendations remained moderate (j = 0.56;
range: 0.18–1.00; p = 0.59). The agreement among
oncologists after adding the 70-gene signature remained
moderate for risk estimations (j = 0.44; range: 0.05–
0.84; p = 0.39) as well as AST recommendations
(j = 0.56; range: 0.18–1.00; p = 0.76).
3.4. Opinion of oncologists about the use of the 70-gene
signature
Seven oncologists (58%) indicated the 70-gene signa-
ture result had additional value and adding the 70-gene
signature result led to a slightly, not signiﬁcantly larger
decrease in the use of AST in these oncologists. On aver-
age, in 19% of the cases the result of the 70-gene signa-
ture was decisive according to the oncologists who
indicated the 70-gene signature had additional value.
C.A. Drukker et al. / European Journal of Cancer 50 (2014) 1045–1054 10514. Discussion
Only a moderate level of agreement for both risk
estimations and treatment decisions was observed
between oncologists when using the clinico-pathologi-
cal factors that are used in current guidelines, such as
age, tumour size, grade and hormone-receptor status.
After providing the 70-gene signature result the level
of agreement in risk estimations among oncologists
increased slightly from moderate (j = 0.55) to substan-
tial (j = 0.61; p = 0.035), showing that classiﬁcation of
patients into high and low risk groups based on the
70-gene signature result may be useful to guide AST
recommendations.Table 3
Levels of agreement among oncologists in risk estimations and adjuvant sys
70-gene signature result to known clinico-pathological factors.The participating oncologists classiﬁed more patients
as high risk compared to the 70-gene signature. This was
followed by recommendations of AST in 92% of the
cases. In 10.8% of the cases a high risk estimation was
changed into a low risk estimation after adding the
70-gene signature result. Overall, a reduction in the
proportion of high risk patients of 7.4% and reduction
of 12.2% in the use of chemotherapy was seen in this
case-selection; these proportions may of course diﬀer
in populations with a diﬀerent distribution of tumour-
characteristics.
Previously reported speciﬁcity rates of the 70-gene
signature (0.56) are higher than AOL (0.53) and St. Gal-
len (0.10) at 5 years of follow-up in a pooled dataset oftemic treatment (AST) recommendations before and after providing the
Table 3 (continued)
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with ER-positive, node-negative breast cancer [14]. This
suggests that the 70-gene signature is a useful tool to
reduce the risk of falsely classifying a patient as high risk
and that the 70-gene signature may help to reduce over-
treatment. An important observation is the variation
among oncologists in risk estimation and AST recom-
mendation. A similar study, where the Oncotype DX
recurrence score was used as a prognostic tool, showed
comparable results, demonstrating that oncologists only
have fair to moderate level of agreement when predict-
ing the recurrence score [15]. Adding the recurrence
score resulted in a decrease in chemotherapy recommen-
dation of 10.8%, which is comparable to the 12.2% seen
in our survey. In our survey, 58% of the oncologists
found the 70-gene signature of additional value.
There are some limitations to this survey. The results
of 12 oncologists are reported; 19 out of 29 responded to
the ﬁrst questionnaire and only 12 out of 29 also
responded to the second questionnaire leading to a
response rate of 41%. Unfortunately, because the num-
ber of participating oncologists was fairly low we were
unable to perform subgroup analyses to evaluate ifoncologists are adherent to the guidelines they indicated
to use. The agreement among oncologists might also be
partly explained by the presence of a few cases at such a
high risk that chemotherapy might be considered stan-
dard of care. Even though not all guidelines included
in this survey for example identify HER2-positive
patients as high risk, the majority of the oncologists con-
sider them eligible for chemotherapy. When excluding
the HER2-positive cases from the analysis, the results
show a moderate agreement in risk estimation and
AST recommendation based on solely clinico-patholog-
ical factors as well as after adding the 70-gene signature
result. The changes in risk estimation and AST recom-
mendations in this survey could also be due to practice
patterns of oncologists and lack of adherence to guide-
lines in general [16]. Only oncologists in Europe were
invited to participate in this survey. A larger survey,
including a larger number of oncologists not only from
Europe, but also from other continents would provide
more detailed information on diﬀerences in breast can-
cer treatment between countries and continents.
In daily clinical practice, the oncologist is faced with
the challenge of tailoring adjuvant systemic therapy for
C.A. Drukker et al. / European Journal of Cancer 50 (2014) 1045–1054 1053each patient, taking the clinico-pathological features of
the tumour, the 70-gene signature result, the patients’
co-morbidities and preferences into account. Prolifera-
tion markers, like Ki67, menopausal status and co-mor-
bidity were unknown in our case-selection and were not
presented in the questionnaires. Providing this kind of
extra information may have further improved the ability
to discriminate between high and low risk cases and may
have inﬂuenced AST recommendation. On the other
hand, providing more proliferation markers and patho-
logical characteristics may not directly result in more
agreement [17]. In clinical practice, gene-expression pro-
ﬁles will likely be used in addition to clinico-pathologi-
cal guidelines, like the way the 70-gene signature was
used in the RASTER study and presented in the cases
in our survey [18].
The follow-up of the RASTER study showed that
patients treated according to the 70-gene signature
who did not receive AST, despite poor clinico-patholog-
ical factors, had a distant recurrence free interval of
100% [18]. Based on these data, the reduction in chemo-
therapy resulting from knowledge of the 70-gene signa-
ture result as presented in this survey, may be justiﬁed.
Especially, since in the RASTER study not only the
70-gene signature result was decisive, but also the doc-
tors’ and patients’ preferences. The St. Gallen 2011 rec-
ommendations and ESMO practice guidelines include
the 70-gene signature as an indicator for AST [19,20].
In conclusion, this survey shows the variability in
guidelines and oncologists’ risk estimations and recom-
mendations of AST in early stage breast cancer patients.
Providing the 70-gene signature result has a modest
impact on risk estimation and AST recommendation.
It may lead to a reduction in the classiﬁcation of high
risk patients and a decrease in the use of chemotherapy.
Most importantly, this survey underlines the need for a
better standardisation tool in clinical decision-making.Funding source
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